Literature DB >> 9578085

Pulmonary lymphomatoid granulomatosis in acquired immunodeficiency syndrome: lesions with Epstein-Barr virus infection.

A K Haque1, J L Myers, S D Hudnall, B B Gelman, R V Lloyd, D Payne, M Borucki.   

Abstract

We report the clinicopathologic characteristics of pulmonary lymphomatoid granulomatosis (LYG) in 11 patients (identified from a series of 330 consecutive patients who underwent autopsy between 1984 and 1995 at the University of Texas Medical Branch at Galveston, Texas) with a diagnosis of acquired immunodeficiency syndrome (AIDS). We used immunohistochemical stains, RNA in situ hybridization (ISH), and gene rearrangement studies to identify the immunophenotype and the presence or absence of Epstein-Barr virus (EBV) infection. All of the patients were men ranging in age from 27 to 65 years (mean age, 38.6 yr). Autopsy lungs of 21 age-matched controls were examined for EBV using ISH; these included 9 patients with AIDS who did not have pulmonary lesions and 12 HIV-negative individuals who died accidentally (mean age, 38.6 yr). All of the 11 pulmonary lesions showed the gross and microscopic characteristics of LYG, with zonal necrosis and prominent angioinvasion. The tumor nodules consisted of a mixture of atypical large lymphocytes, with vesicular nuclei and prominent nucleoli and with a background of small and intermediate-size lymphocytes, histiocytes, and plasma cells. The large lymphocytes were CD20 positive, consistent with a B-cell phenotype. Ten of the 11 cases demonstrated EBV1-encoded RNA and CD20 positivity in the large, atypical lymphocytes by double labeling. One patient showed EBV positivity in CD20-negative, CD45RO-positive large cells, but these cells were CD3 negative and showed a monoclonal heavy chain gene rearrangement by polymerase chain reaction, indicating that these were of B-cell origin. Aberrant CD43 coexpression was identified in four cases. EBV latent membrane protein was demonstrated in 9 of 11 cases by immunohistochemical stains. The lungs of all of the 21 control patients were negative for EBV by ISH. We conclude that, in our series, AIDS-associated LYG is a B-cell neoplasm and that it has a strong association with EBV infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578085

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

1.  Angiocentric lesions of the head and neck.

Authors:  Cynthia M Magro; Molly Dyrsen
Journal:  Head Neck Pathol       Date:  2008-05-27

Review 2.  Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder.

Authors:  Christopher Melani; Elaine S Jaffe; Wyndham H Wilson
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

3.  A case of lymphomatoid granulomatosis with central nervous system involvement successfully treated with IFNα.

Authors:  Yoshitaka Yamasaki; Satoshi Morishige; Satoru Komaki; Takuya Furuta; Hiroshi Koga; Shuki Oya; Takayuki Nakamura; Maki Yamaguchi; Kazutoshi Aoyama; Fumihiko Mouri; Koichi Osaki; Takekuni Nakama; Koichi Ohshima; Motohiro Morioka; Koji Nagafuji
Journal:  Int J Hematol       Date:  2021-06-22       Impact factor: 2.490

4.  Murine gammaherpesvirus 68 infection of IFNgamma unresponsive mice: a small animal model for gammaherpesvirus-associated B-cell lymphoproliferative disease.

Authors:  Katherine S Lee; Steve D Groshong; Carlyne D Cool; Bette K Kleinschmidt-DeMasters; Linda F van Dyk
Journal:  Cancer Res       Date:  2009-06-16       Impact factor: 12.701

5.  Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report.

Authors:  Cecilia T Costiniuk; Jason Karamchandani; Ali Bessissow; Jean-Pierre Routy; Jason Szabo; Charles Frenette
Journal:  BMC Infect Dis       Date:  2018-05-08       Impact factor: 3.090

6.  Lymphomatoid granulomatosis in a renal transplant patient.

Authors:  François Cachat; Kathleen Meagher-Villemure; Jean-Pierre Guignard
Journal:  Pediatr Nephrol       Date:  2003-06-12       Impact factor: 3.651

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.